




Umeclidinium

Revised: December 15, 2023.

CASRN: 869185-19-3



Drug Levels and Effects

Summary of Use during Lactation

Although no published data exist on the use of umeclidinium during breastfeeding, it produces low systemic maternal serum levels and any drug in breastmilk would not be absorbed by the infant. The risk to the breastfed infant of maternal umeclidinium inhalation is small. Combination products such as Anoro Ellipta are likely to be acceptable for similar reasons.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Acidinium, Tiotropium

Substance Identification

Substance Name

Umeclidinium

CAS Registry Number

869185-19-3

Drug Class

Breast Feeding

Lactation

Milk, Human

Parasympatholytics

Muscarinic Antagonists

Bronchodilator Agents